SYR-472

DRUG7 trials

Sponsors

Takeda

Conditions

Diabetes MellitusHealthyType 2 Diabetes Mellitus

Phase 1

A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets

CompletedNCT02372097

Start: 2015-03-31End: 2015-04-30Updated: 2023-12-22

Phase 2

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

CompletedNCT00653185

TakedaDiabetes Mellitus

Start: 2007-05-31End: 2008-03-31Updated: 2016-06-22

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

CompletedNCT00760344

TakedaDiabetes Mellitus

Start: 2007-03-31End: 2008-03-31Updated: 2016-06-22

Phase 3

Long-term Study of SYR-472

CompletedNCT01431807

TakedaDiabetes Mellitus

Start: 2011-09-01End: 2013-06-01Updated: 2023-12-14

Double-blind Comparative Study of SYR-472

CompletedNCT01632007

TakedaDiabetes Mellitus

Start: 2012-05-01End: 2013-07-01Target: 245Updated: 2023-12-11

SYR-472 Open-label Study

CompletedNCT01751360

TakedaDiabetes Mellitus

Start: 2013-04-01End: 2013-08-01Updated: 2023-12-11

A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

CompletedNCT02324569

TakedaType 2 Diabetes Mellitus

Start: 2014-12-27End: 2016-12-28Updated: 2023-12-12

Related Papers

Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.

2015-01-1963 citations